HTR1F
5-hydroxytryptamine receptor 1F
As of the edition of 20 October 2026, HTR1F (5-hydroxytryptamine receptor 1F, UniProt P30939) has 3 drugs tested at it and 6 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30939
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Nervous system; Chemically induced; Mental health; Ear, nose and throat; Infections; Lungs and airways; Mouth and teeth
- Registered trials of its drugs
- 54
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lasmiditan | Marketed | Phase 3 | Ends 2037 |
| Eletriptan | Marketed | Phase 4 | none listed |
| Almotriptan | Marketed | Phase 4 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| Johnson & Johnson | Route B |
| Almirall | Route B |
The other 3 companies at HTR1F
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HTR1F, ranked, with the facts behind eachRequest access. Nothing is shown until you do.